Seth Flaum

Much of Seth’s work is cross-border, spanning the United States, Europe, Asia, and the Middle East. He is widely recognized for his Japan practice, advising Japanese companies expanding abroad and companies doing business in Japan with Japanese partners. 

Seth previously served as in-house counsel at a large global pharmaceutical company, where he led a team of lawyers and business professionals responsible for intellectual property and business development. That experience gives him a firsthand understanding of the commercial realities that drive dealmaking. 

Seth’s practice extends to public and private mergers and acquisitions (M&A), with particular experience in earnouts and contingent value rights agreements, as well as antitrust filings, US Securities and Exchange Commission and Financial Industry Regulatory Authority matters, and corporate governance. 

Additionally, Seth counsels senior executives and serves as outside general counsel to companies seeking day-to-day support in running a life sciences business. His combination of international perspective, sector experience, and in-house insight allows him to guide clients from the earliest stages of an opportunity through execution and beyond. 

See less

• Represented Soleno Therapeutics, a rare disease company, in its acquisition by Neurocrine Biosciences for $53.00 per share in cash, a total equity value of $2.9 billion. The deal added VYKAT XR (diazoxide choline), the first and only FDA-approved treatment for hyperphagia in Prader-Willi syndrome, to Neurocrine’s portfolio 

• Represented Pacira BioSciences, a leader in non-opioid pain management, in an exclusive worldwide license and collaboration with Toronto-based AmacaThera for AMT-143, a long-acting ropivacaine formulation for postsurgical pain built on a hydrogel drug delivery platform. The deal is valued at up to $230 million, comprising $5 million upfront and up to $225 million in development and sales milestones, plus tiered royalties 

See less